CSL (OTCMKTS:CSLLY) Sets New 12-Month Low – Here’s Why

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) reached a new 52-week low on Wednesday . The stock traded as low as $24.3140 and last traded at $24.3140, with a volume of 8243 shares changing hands. The stock had previously closed at $25.08.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CSLLY. Royal Bank Of Canada downgraded CSL from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, February 11th. Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

CSL Stock Performance

The stock’s 50 day simple moving average is $50.38 and its 200 day simple moving average is $58.51. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.46 and a quick ratio of 1.12.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.